BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study

  • Gautam Borthakur*
  • , Yishai Ofran
  • , Martin S. Tallman
  • , James Foran
  • , Geoffrey L. Uy
  • , John F. DiPersio
  • , Margaret M. Showel
  • , Avichai Shimoni
  • , Arnon Nagler
  • , Jacob M. Rowe
  • , Jessica K. Altman
  • , Michal Abraham
  • , Amnon Peled
  • , Stephen Shaw
  • , Osnat Bohana-Kashtan
  • , Ella Sorani
  • , Yaron Pereg
  • , Adam Foley-Comer
  • , Galia Oberkovitz
  • , Tzipi M. Lustig
    • Irit Glicko-Kabir, Arnon Aharon, Abi Vainstein-Haras, Shaul E. Kadosh, Emil Samara, Ahmed N. Al-Rawi, Naveen Pemmaraju, Carlos Bueso-Ramos, Jorge E. Cortes, Michael Andreeff*
*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Fingerprint

Dive into the research topics of 'BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry